MET in NSCLC

Episode
135
Soundcloud
Share

This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.

Guest
Narjust Florez Headshot 2022
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
D. Ross Camidge, MD, PhD
D. Ross Camidge

MD, PhD

Director of Thoracic Oncology
University of Colorado Cancer Center

Other Podcast

Lung Cancer in Brazil
Episode
141
Patient Advocacy Groups Podcast
Episode
140
Radon Podcast
Episode
139
FDA Approval: Adagrasib
Episode
138